Characterization of changes in serum anti-glycan antibodies in Crohn's disease--a longitudinal analysis |
| |
Authors: | Rieder Florian Lopez Rocio Franke Andre Wolf Alexandra Schleder Stephan Dirmeier Andrea Schirbel Anja Rosenstiel Philip Dotan Nir Schreiber Stefan Rogler Gerhard Klebl Frank |
| |
Institution: | Department of Internal Medicine I, University of Regensburg, Regensburg, Germany. florian.rieder@t-online.de |
| |
Abstract: | IntroductionAnti-glycan antibodies are a promising tool for differential diagnosis and disease stratification of patients with Crohn''s disease (CD). We longitudinally assessed level and status changes of anti-glycan antibodies over time in individual CD patients as well as determinants of this phenomenon.Methods859 serum samples derived from a cohort of 253 inflammatory bowel disease (IBD) patients (207 CD, 46 ulcerative colitis (UC)) were tested for the presence of anti-laminarin (Anti-L), anti-chitin (Anti-C), anti-chitobioside (ACCA), anti-laminaribioside (ALCA), anti-mannobioside (AMCA) and anti-Saccharomyces cerevisiae (gASCA) antibodies by ELISA. All patients had at least two and up to eleven serum samples taken during the disease course.ResultsMedian follow-up time for CD was 17.4 months (Interquartile range (IQR) 8.0, 31.6 months) and for UC 10.9 months (IQR 4.9, 21.0 months). In a subgroup of CD subjects marked changes in the overall immune response (quartile sum score) and levels of individual markers were observed over time. The marker status (positive versus negative) remained widely stable. Neither clinical phenotype nor NOD2 genotype was associated with the observed fluctuations. In a longitudinal analysis neither changes in disease activity nor CD behavior led to alterations in the levels of the glycan markers. The ability of the panel to discriminate CD from UC or its association with CD phenotypes remained stable during follow-up. In the serum of UC patients neither significant level nor status changes were observed.ConclusionsWhile the levels of anti-glycan antibodies fluctuate in a subgroup of CD patients the antibody status is widely stable over time. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|